UFP Technologies, Inc.
$290.85-$8.08 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.7B
- P/E
- 25.4x
- EV / EBITDA
- 16.8x
- Revenue
- $602.8M
- Net margin
- 11.3%
- ROCE
- 16.0%
Price chart
Technical chartScreen technicals →+38.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -0.2%
- 3M
- -4.4%
- 6M
- +29.4%
- 1Y
- +38.6%
- 5Y
- +318.8%
52-week range
Day change -$8.08 (-2.7%) from $299 to $291 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in UFPT, bought on each weekday since 2021.
News & filings
What UFP Technologies filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was 9.4 times interest costs.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States.
Read moreShow less
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 7.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.7B
- P/E
- 25.4x
- P/B
- 4.1x
- EV / EBITDA
- 16.8x
- EV / Sales
- 3.1x
- P/S
- 2.9x
- 52-week high
- $334.84
- 52-week low
- $185.45
Profitability
- Operating margin
- 15.4%
- Net margin
- 11.3%
- EBITDA margin
- 18.5%
- ROE
- 16.1%
- ROCE
- 16.0%
- ROA
- 10.4%
- Asset turnover
- 0.92
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $602.8M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 19.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 19.4%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 15.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $79.0M
Solvency
- Current ratio
- 2.68
- Debt / Equity
- 0.36
- Debt / Assets
- 0.24
- CFO / Net profit
- 1.35
- Cash / Market cap
- 1.2%
Where the revenue went
Of every $100 of FY2025 revenue, $11 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $432.4M |
| Revenue | Gross profit | $170.4M |
| Gross profit | Operating expenses | $77.4M |
| Gross profit | Operating income | $93.0M |
| Operating income | Pretax income | $82.5M |
| Operating income | Interest and other expense | $10.5M |
| Pretax income | Tax and other | $14.2M |
| Pretax income | Net income | $68.3M |
Revenue and net profit
Revenue grew 19.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $353.8M | $41.8M |
| FY2023 | $400.1M | $44.9M |
| FY2024 | $504.4M | $59.0M |
| FY2025 | $602.8M | $68.3M |
Cash flows
FY2025: $91.9M from operations, $79.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $17.7M | $4.0M |
| FY2023 | $41.3M | $30.8M |
| FY2024 | $66.6M | $56.9M |
| FY2025 | $91.9M | $79.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $602.8M+19.5%1Y
- EBITDA
- $111.5M+16.4%1Y
- Net profit
- $68.3M+15.8%1Y
- Cash from operations
- $91.9M+38.0%1Y
- Free cash flow
- $79.0M+38.7%1Y
- Revenue CAGR, 3Y
- 19.4%
- Net profit CAGR, 3Y
- 17.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $602.8M | $111.5M | $68.3M | $79.0M | 16.1% | +19.5% | +15.8% |
Monthly returns
Month-by-month returns of UFPT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $655.1M |
| Current assets | $201.0M |
| Non-current assets | $454.1M |
| Liabilities | $231.2M |
| Current liabilities | $74.9M |
| Non-current liabilities | $156.3M |
| Equity | $423.9M |
| Paid-in capital | $45.9M |
| Retained earnings | $374.8M |
| Treasury stock | $590.0k |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; UFPT highlighted.
P/E against peers
UFPT trades at 25.4x earnings against a peer median of -15.5x.
Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc., SELLAS Life Sciences Group, Inc., Biohaven Ltd., Sionna Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| UFP Technologies, Inc.UFPTthis company | $1.7B | 25.4x | 4.1x | 16.1% | 16.8x |
| Rapport Therapeutics, Inc.RAPP | $1.8B | — | -178.2x | -23.0% | — |
| Surgery Partners, Inc.SGRY | $1.8B | -23.0x | 1.0x | -4.5% | 9.9x |
| SELLAS Life Sciences Group, Inc.SLS | $1.8B | -66.2x | 25.1x | -37.9% | -60.4x |
| Biohaven Ltd.BHVN | $1.7B | -2.3x | 33.0x | -1418.8% | -2.4x |
| Agios Pharmaceuticals, Inc.AGIO | $1.7B | -4.1x | 1.4x | -34.6% | -3.6x |
| Sionna Therapeutics, Inc.SION | $1.7B | -22.7x | 5.6x | -24.5% | -18.7x |
| Taysha Gene Therapies, Inc.TSHA | $1.7B | -15.5x | 6.9x | -44.1% | -13.4x |
| Novavax, Inc.NVAX | $1.7B | 3.8x | -13.1x | -344.7% | 3.4x |
| Peer median | — | -15.5x | 3.5x | -36.3% | -3.6x |
Year-to-date ROI
UFPT since 1 January, against earlier years.
Historical volatility
UFPT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 12.6% |
| FY2023 | 15.3% |
| FY2024 | 16.7% |
| FY2025 | 15.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $602.8M |
| Cost of revenueCost Of Revenue | $432.4M |
| Gross profitGross Profit | $170.4M |
| Operating expensesOperating Expense | $77.4M |
| Selling, general and administrativeSelling General And Administration | $77.4M |
| Total expensesTotal Expenses | $509.8M |
| Operating incomeOperating Income | $93.0M |
| Interest and other | |
| Pretax incomePretax Income | $82.5M |
| TaxTax Provision | $14.2M |
| Net incomeNet Income | $68.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $655.1M |
| Current assetsCurrent Assets | $201.0M |
| Non-current assetsTotal Non Current Assets | $454.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $231.2M |
| Current liabilitiesCurrent Liabilities | $74.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $156.3M |
| EquityTotal Equity Gross Minority Interest | $423.9M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $91.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $91.9M |
| Net income, continuing operationsNet Income From Continuing Operations | $68.3M |
| Depreciation and amortisationDepreciation And Amortization | $19.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $19.1M |
| Stock-based compensationStock Based Compensation | $8.8M |
| Deferred taxDeferred Tax | $5.1M |
| Deferred income taxDeferred Income Tax | $5.1M |
| Operating gains and lossesOperating Gains Losses | -$80.0k |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $40.0k |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | -$120.0k |
| Change in working capitalChange In Working Capital | -$9.7M |
| Other non-cash itemsOther Non Cash Items | $260.0k |
| Dividend received (operating)Dividend Received Cfo | $0.00 |
| Investing cash flowInvesting Cash Flow | -$27.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$27.6M |
| Capital expenditureCapital Expenditure | -$12.9M |
| Purchase of PP&EPurchase Of PPE | -$12.9M |
| Sale of PP&ESale Of PPE | $50.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$12.9M |
| AcquisitionsPurchase Of Business | -$14.7M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$14.7M |
| Purchase of investment propertiesPurchase Of Investment Properties | $0.00 |
| Net investment properties purchase and saleNet Investment Properties Purchase And Sale | $0.00 |
| Dividends received (investing)Dividends Received Cfi | $0.00 |
| Financing cash flowFinancing Cash Flow | -$58.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$58.2M |
| Debt issuedIssuance Of Debt | $68.7M |
| Debt repaidRepayment Of Debt | -$122.7M |
| Net debt issuedNet Issuance Payments Of Debt | -$54.0M |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $68.7M |
| Long-term debt repaidLong Term Debt Payments | -$122.7M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$54.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $190.0k |
| Other financing chargesNet Other Financing Charges | -$4.4M |
| Change in cashChanges In Cash | $6.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 70.0% |
| Cash at the start of the yearBeginning Cash Position | $13.4M |
| Cash at the end of the yearEnd Cash Position | $20.3M |
| Free cash flowFree Cash Flow | $79.0M |
| Supplemental |
Learn while you research
Academy chapters picked for UFP Technologies, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read